Health Canada approves AVT 04 a biosimilar to Stelara (ustekinumab)
Alvotech and JAMP Pharma Group, a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced that Health Canada has granted JAMP Pharma marketing authorization for AVT 04, a biosimilar to Stelara (ustekinumab) developed by Alvotech. AVT04 will be marketed under the brand name Jamteki
The currently approved presentations of Jamteki are a 45mg/0.5mL pre-filled syringe with a passive safety device for subcutaneous injection (PFS-SD) and the 90mg/mL PFS-SD. This is the second biosimilar to receive marketing authorization, developed under an exclusive commercialization partnership between Alvotech and JAMP Pharma. Last year, the partners launched Simlandi, a biosimilar to Humira (adalimumab).
“The introduction of Jamteki is in line with our current biosimilar product offering and showcases JAMP Pharma’s commitment to evolve in this market,” said Louis Pilon, President and CEO at JAMP Pharma. “Alvotech is an innovative and strategic partner, enabling Canadian patients to benefit from ustekinumab at a lower cost. Patients will also benefit from the expertise of our Patient Support Program – JAMP Care – for an optimal and seamless transition.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.